# Clinical Trial of Neoadjuvant Targeted Treatment to NSCLC Patients

> **NCT03203590** · PHASE3 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 590 (estimated)

## Conditions studied

- 2-year Disease-Free Survival

## Interventions

- **DRUG:** Oral Navelbine + Carboplatin
- **DRUG:** Gefitinib

## Key facts

- **NCT ID:** NCT03203590
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-09
- **Primary completion:** 2026-01
- **Final completion:** 2026-01
- **Target enrollment:** 590 (ESTIMATED)
- **Last updated:** 2017-06-29

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03203590

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03203590, "Clinical Trial of Neoadjuvant Targeted Treatment to NSCLC Patients". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03203590. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*